Exhibit 10.1


 


Director
NOMINATION Agreement


 


THIS Director
NOMINATION Agreement (this “Agreement”) is made and entered into as of March 8, 2021, by and among
InnovAge Holding Corp., a Delaware corporation (the “Company”), Ignite Aggregator LP, a Delaware limited
partnership (together with its affiliated investment entities, “Apax Partners”), Welsh, Carson, Anderson &
Stowe XII, L.P., Welsh, Carson, Anderson & Stowe XII Delaware, L.P., Welsh, Carson, Anderson & Stowe XII Delaware
II, L.P., Welsh, Carson, Anderson & Stowe XII Cayman, L.P., WCAS XII Co-Investors LLC, WCAS Management Corporation and
WCAS Co-Invest Holdco, L.P. (together with Welsh, Carson, Anderson & Stowe XII, L.P., Welsh, Carson, Anderson &
Stowe XII Delaware, L.P., Welsh, Carson, Anderson & Stowe XII Delaware II, L.P., Welsh, Carson, Anderson & Stowe
XII Cayman, L.P., WCAS XII Co-Investors LLC, WCAS Management Corporation, “WCAS” and, together with Apax Partners,
the “Sponsors”). This Agreement shall become effective (the “Effective Date”) upon the closing
of the Company’s initial public offering (the “IPO”) of shares of its common stock, par value $0.001 per
share (the “Common Stock”).


 


WHEREAS, as of the
date hereof, the Sponsors collectively own a majority of the outstanding equity interests of TCO Group Holdings, L.P.;


 


WHEREAS, the Sponsors
are contemplating causing the Company to effect the IPO;


 


WHEREAS, in consideration
of the Sponsors agreeing to undertake the IPO, the Company has agreed to permit the Sponsors to designate persons for nomination
for election to the board of directors of the Company (the “Board”) following the Effective Date on the terms
and conditions set forth herein;


 


NOW, THEREFORE, in
consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of
which are hereby acknowledged, each of the parties to this Agreement agrees as follows:


 


		1.	Board Nomination Rights.



 


		(a)	From the Effective Date, the Sponsors have the right to designate (i) all of the nominees for election to the Board for
so long as the Sponsors collectively beneficially own at least 40% of the total number of shares of the Company’s Common
Stock collectively beneficially owned by the Sponsors upon completion of the IPO (including the underwriters’ exercise of
any option to purchase additional shares contemplated on the cover page of the prospectus relating to the IPO), as adjusted
for any reorganization, recapitalization, stock dividend, stock split, reverse stock split or similar changes in the Company’s
capitalization (the “Original Amount”); (ii) 40% of the nominees for election to the Board for so long
as the Sponsors collectively beneficially own less than 40% but at least 30% of the Original Amount; (iii) 30% of the nominees
for election to the Board for so long as the Sponsors collectively beneficially own less than 30% but at least 20% of the Original
Amount; (iv) 20% of the nominees for election to the Board for so long as the Sponsors collectively beneficially own less
than 20% but at least 10% of the Original Amount; and (v) one (1) of the nominees for election to the Board for so long
as the Sponsors collectively beneficially own at least 5% of the Original Amount (such persons, the “Nominees”).
If TCO Group Holdings, L.P. is dissolved after IPO, then each of Apax Partners and WCAS will be permitted to nominate (A) up
to three (3) Directors (as defined below) so long as it owns at least 25% of the Original Amount, (B) up to two (2) Directors
so long as it owns at least 15% of the Original Amount and (C) one (1) Director so long as it owns at least 5% of the
Original Amount. The Sponsors may assign such nomination rights to their Affiliates (as defined below).



 






     


     


    

 


		(b)	In the event that any Sponsor has nominated less than the total number of designees that such Sponsor shall be entitled to
nominate pursuant to Section 1(a), such Sponsor shall have the right, at any time, to nominate such additional designees
to which it is entitled, in which case, the Company and the Directors shall take all necessary corporation action, to the fullest
extent permitted by applicable law (including with respect to fiduciary duties under Delaware law), to (x) enable such Sponsor
to nominate and effect the election or appointment of such additional individuals, whether by increasing the size of the Board,
or otherwise and (y) to designate such additional individuals nominated by such Sponsor to fill such newly created vacancies
or to fill any other existing vacancies.



 


		(c)	The Company shall pay all reasonable out-of-pocket expenses incurred by any Nominee in connection with the performance of his
or her duties as a Director and in connection with his or her attendance at any meeting of the Board.



 


		(d)	“Beneficially Own” shall mean that a specified person has or shares the right, directly or indirectly, through
any contract, arrangement, understanding, relationship or otherwise, to vote shares of capital stock of the Company. “Affiliate”
of any person shall mean any other person controlled by, controlling or under common control with such person; where “control”
(including, with its correlative meanings, “controlling,” “controlled by” and “under
common control with”) means possession, directly or indirectly, of power to direct or cause the direction of management
or policies (whether through ownership of securities, by contract or otherwise).



 


		(e)	“Director” means any member of the Board.



 


		(f)	No reduction in the number of shares of Common Stock that each Sponsor Beneficially Owns shall shorten the term of any incumbent
Director. At the Effective Date, the Board shall be comprised of ten (10) members and the initial members shall be Maureen
Hewitt, John Ellis Bush, Andrew Cavanna, Caroline Dechert, Edward Kennedy, Jr., Pavithra Mahesh, Thomas Scully, Marilyn Tavenner,
Sean Traynor and Richard Zoretic. Andrew Cavanna and Pavithra Mahesh shall constitute the “Apax Nominees” and Caroline
Dechert, Thomas Scully and Sean Traynor shall constitute the “WCAS Nominees.” The Sponsors may change the respective
individuals designated as such Apax Nominees and WCAS Nominees by providing notice to the Company.



 






    2 


     


    

 


		(g)	In the event that any Nominee shall cease to serve for any reason, the Sponsor that nominated such Nominee shall be entitled
to designate such person’s successor in accordance with this Agreement (regardless of each Sponsor’s Beneficial Ownership
of Common Stock at the time of such vacancy) and the Board shall promptly fill the vacancy with such successor nominee; it being
understood that any such designee shall serve the remainder of the term of the Director whom such designee replaces.



 


		(h)	If a Nominee is not appointed or elected to the Board because of such person’s death, disability, disqualification, withdrawal
as a Nominee or for other reason is unavailable or unable to serve on the Board, the applicable Sponsor shall be entitled to designate
promptly another Nominee and the director position for which the original Nominee was nominated shall not be filled pending such
designation.



 


		(i)	So long as a Sponsor has the right to nominate at least one Nominee under this Section 1 or any such Nominee is
serving on the Board, the Company shall maintain in effect at all times directors and officers indemnity insurance coverage reasonably
satisfactory to the Sponsors, and the Company’s Amended and Restated Certificate of Incorporation and Bylaws (each as may
be further amended, supplemented or waived in accordance with its terms) shall at all times provide for indemnification, exculpation
and advancement of expenses to the fullest extent permitted under applicable law.



 


		(j)	At any time that a Sponsor shall have any nomination rights under this Section 1, the Company shall not increase
or decrease the number of Directors serving on the Board without the prior written consent of the Sponsors having such rights.



 


		(k)	At such time as the Company ceases to be a “controlled company” and is required by applicable law or Nasdaq (the
 “Exchange”) listing standards to have a majority of the Board comprised of “independent directors”
(subject in each case to any applicable phase-in periods), the Nominees shall include a number of persons that qualify as “independent
directors” under applicable law and the Exchange listing standards such that, together with any other “independent
directors” then serving on the Board that are not Nominees, the Board is comprised of a majority of “independent directors”;
provided that at any time that a Sponsor shall have any nomination rights under this Section 1, (i) each
such Sponsor shall be entitled to nominate at least one (1) Nominee who does not qualify as an “independent director”
and (ii) the number of “independent directors” required to be nominated by any Sponsor pursuant to this provision
shall not be greater than the number of Nominees required to be “independent directors” pursuant to this provision
to be nominated by any other Sponsor with the right to nominate the same number of, or more, Nominees as such Sponsor; provided,
however, in the event that the number of required “independent directors” is odd, the Sponsors agree to work
in good faith to collectively nominate one such “independent director;” provided, further, however,
that to the extent a mutually agreeable “independent director” cannot be agreed upon, that the Board shall have the
right to expand its size by one and to nominate and appoint such required “independent director” to fill the resulting
vacancy, provided that such nominee is acceptable to each Sponsor.



 






    3 


     


    

 


		(l)	At any time that a Sponsor shall have any nomination rights under this Section 1, the Company shall not take any
action, including making or recommending any amendment to Company’s Amended and Restated Certificate of Incorporation or
Bylaws (each as may be further amended, supplemented or waived in accordance with its terms) that could reasonably be expected
to adversely affect a Sponsor’s rights under this Agreement, in each case without the prior written consent of the adversely
affected Sponsor.



 


		(m)	Each Sponsor hereby agrees to be present in person or by proxy and vote or cause to be voted all Common Stock Beneficially
Owned by such Sponsor at each annual or special meeting of the Company at which Directors of the Company are to be elected, in
favor of, or to take all actions by written consent in lieu of any such meeting as are necessary, or other necessary action, to
cause the election of the Nominees described in Section 1(a) in accordance with, and otherwise to achieve the
composition of the Board and effect the intent of, the provisions of this Section 1.



 


		(n)	The Company recognizes that Nominees (i) will from time to time receive non-public information concerning the
Company, and (ii) may share such information with other individuals associated with the Sponsor that designated such Nominee.
The Company hereby irrevocably consents to such sharing. Each Sponsor agrees that it will keep confidential and not disclose or
divulge to any third party any confidential information regarding the Company it receives from the Company or a Nominee, unless
such information (x) is known or becomes known to the public in general, (y) is or has been independently developed or
conceived by such Sponsor without use of the Company’s confidential information or (z) is or has been made known or
disclosed to such Sponsor by a third party without a breach of any obligation of confidentiality such third party may have; provided,
however, that a Sponsor may disclose confidential information (I) to its Affiliates (other than portfolio companies),
(II) to each of its and its Affiliate’s (other than portfolio companies) attorneys, accountants, consultants, advisors
and other professionals to the extent necessary to obtain their services in connection with evaluating the information, or (III) as
may be required by law or legal, judicial or regulatory process or requested by any regulatory or self-regulatory authority or
examiner, provided that such Sponsor takes reasonable steps to minimize the extent of any required disclosure described
in this clause (III).



 






    4 


     


    

 


2.     Company
Obligations. The Company agrees that prior to the date that each Sponsor and its Affiliates cease to Beneficially Own shares
of Common Stock representing at least 5% of the Original Amount, (i) each Nominee is included in the Board’s slate of
nominees to the stockholders (the “Board’s Slate”) for each election of Directors; and (ii) each
Nominee is included in the proxy statement prepared by management of the Company in connection with soliciting proxies for every
meeting of the stockholders of the Company called with respect to the election of members of the Board (each, a “Director
Election Proxy Statement”), and at every adjournment or postponement thereof, and on every action or approval by written
consent of the stockholders of the Company or the Board with respect to the election of members of the Board. Each Sponsor will
promptly report to the Company after such Sponsor ceases to Beneficially Own shares of Common Stock representing at least 5% of
the total voting power of the Original Amount, such that Company is informed of when this obligation terminates. The calculation
of the number of Nominees that each Sponsor is entitled to nominate to the Board’s Slate for any election of Directors shall
be based on the percentage of the Original Amount Beneficially Owned by each Sponsor immediately prior to the mailing to shareholders
of the Director Election Proxy Statement relating to such election (or, if earlier, the filing of the definitive Director Election
Proxy Statement with the U.S. Securities and Exchange Commission). Unless a Sponsor notifies the Company otherwise prior to the
mailing to shareholders of the Director Election Proxy Statement relating to an election of Directors, the Nominees for such election
shall be presumed to be the same Nominees currently serving on the Board, and no further action shall be required of any Sponsor
for the Board to include such Nominees on the Board’s Slate; provided that, in the event a Sponsor is no longer entitled
to nominate the full number of Nominees then serving on the Board, such Sponsor shall provide advance written notice to the Company,
of which currently servicing Nominee(s) shall be excluded from the Board’s Slate, and of any other changes to the list
of Nominees. If a Sponsor fails to provide such notice prior to the mailing to shareholders of the Director Election Proxy Statement
relating to such election (or, if earlier, the filing of the definitive Director Election Proxy Statement with the U.S. Securities
and Exchange Commission), a majority of the independent directors then serving on the Board shall determine which of the Nominees
of such Sponsor then serving on the Board will be included in the Board’s Slate. Furthermore, the Company agrees for so long
as the Company qualifies as a “controlled company” under the rules of the Exchange the Company will elect to be
a “controlled company” for purposes of the Exchange and will disclose in its annual meeting proxy statement that it
is a “controlled company” and the basis for that determination. The Company and the Sponsors acknowledge and agree
that, as of the Effective Date, the Company is a “controlled company.” The Company agrees to provide written notice
of the preparation of a Director Election Proxy Statement to the Sponsors at least 20 business days, but no more than 40 business
days, prior to the earlier of the mailing and the filing date of any Director Election Proxy Statement.


 


		3.	Governance.



 


		(a)	Protective Provisions. Notwithstanding any other provision of this Agreement and to the fullest extent permitted by
applicable law, in addition to the approval of the Directors, the following actions described in this Section 3(a) (collectively,
the “Consent Matters”) shall require the prior written consent of Apax Partners and/or WCAS as set out below:



 


		i.	none of the following actions shall be taken by the Company, including any proposal by the Board to be put to the vote of the
stockholders of the Company with respect thereto, without (A) the prior written consent of Apax Partners for so long as Apax
Partners owns at least 5% of the Original Amount and (B) the prior written consent of WCAS for so long as WCAS owns at least
5% of the Original Amount (except as set forth in the proviso in Section 3(a)(I)):



 






    5 


     


    

 


		I.	amending, altering or changing, or waiving any rights under, this Agreement, the organizational documents, including the Amended
and Restated Certificate of Incorporation or the Bylaws of the Company, (which shall also be subject to Section 5)
and/or the organizational documents of any subsidiary of the Company; provided that, notwithstanding the foregoing, for
so long as Apax Partners or WCAS, as applicable, own any outstanding Common Stock, any amendment, alteration, or change to, or
waiver under, other organizational documents, including the Amended and Restated Certificate of Incorporation or the Bylaws of
the Company, and/or the organizational documents of any subsidiary of the Company that would adversely affect in any respect any
rights specific to Apax Partners or WCAS shall (subject to applicable law) require the written consent of Apax Partners or WCAS,
as applicable;



 


		II.	authorizing or issuing any equity securities of the Company having rights, preferences or privileges that are superior or senior
to the outstanding Common Stock (or any securities convertible or exchangeable therefor pursuant to their terms);



 


		III.	any transaction with any stockholder or Affiliate of a stockholder or any Director or officer of the Company or any of its
subsidiaries (other than employment agreements with officers not otherwise affiliated with a stockholder);



 


		IV.	winding up the Company; and



 


		V.	entering into any agreement with respect to the matters described in the foregoing clauses (I) through (IV) or taking
any such action indirectly.



 






    6 


     


    

 


		ii.	none of the following actions shall be taken by the Company, including any proposal by the Board to be put to the vote of the
stockholders of the Company with respect thereto, without (A) the prior written consent of Apax Partners for so long as Apax
Partners owns at least 20% of the Original Amount and (B) the prior written consent of WCAS for so long as WCAS owns at least
20% of the Original Amount:



 


		I.	the declaration or payment of any dividend or other distribution to the stockholders by the Company or redemption, repurchase
or exchange (as applicable) of any equity securities of the Company;



 


		II.	issuing or granting any equity securities of the Company or its subsidiaries, other than grants under the Company’s 2021
Omnibus Incentive Plan;



 


		III.	engaging in any mergers, acquisitions, business combinations or similar transactions or entering into any arrangements or agreements
relating to joint ventures or strategic partnerships with a value of such transaction or arrangement exceeding $10.0 million; and



 


		IV.	entry by the Company into any agreement with respect to the matters described in the foregoing clauses (I) through (III) or
taking any such action indirectly.



 


4.     Committees.
From and after the Effective Date hereof until such time as each Sponsor and its Affiliates cease to Beneficially Own Common Stock
representing at least 5% of the Original Amount, each Sponsor shall have the right to designate one member of each committee of
the Board, provided that any such designee shall be a Director and shall be eligible to serve on the applicable committee
under applicable law or listing standards of the Exchange, including any applicable independence requirements (subject in each
case to any applicable exceptions, including those for newly public companies and for “controlled companies,” and any
applicable phase-in periods). Any additional members shall be determined by the Board. Nominees designated to serve on a Board
committee shall have the right to remain on such committee until the next election of Directors, regardless of the number of shares
of Common Stock the Sponsor Beneficially Owns following such designation. Unless a Sponsor notifies the Company otherwise prior
to the time the Board takes action to change the composition of a Board committee, and to the extent the applicable Sponsor Beneficially
Owns the requisite percentage of the Original Amount for such Sponsor to nominate a Board committee member at the time the Board
takes action to change the composition of any such Board committee, any Nominee currently designated by the applicable Sponsor
to serve on a committee shall be presumed to be re-designated for such committee.


 






    7 


     


    

 


5.     Amendment
and Waiver. Any provision of this Agreement may be amended or waived if, but only if, such amendment or waiver is in writing
and is signed, in the case of an amendment, by the Company and each Sponsor owning at least 5% of the Original Amount, or in the
case of a waiver, by the party against whom the waiver is to be effective. No failure or delay by any party in exercising any right,
power or privilege hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other
or further exercise thereof or the exercise of any other right, power or privilege. The rights and remedies herein provided shall
be cumulative and not exclusive of any rights or remedies provided by law. The Sponsors shall not be obligated to nominate all
(or any) of the Nominees they are entitled to nominate pursuant to this Agreement for any election of Directors but the failure
to do so shall not constitute a waiver of their rights hereunder with respect to future elections; provided, however,
that in the event a Sponsor fails to nominate all (or any) of the Nominees it is entitled to nominate pursuant to this Agreement
prior to the mailing to shareholders of the Director Election Proxy Statement relating to such election (or, if earlier, the filing
of the definitive Director Election Proxy Statement with the U.S. Securities and Exchange Commission), the Compensation, Nominating
and Governance Committee of the Board shall be entitled to nominate individuals in lieu of such Nominees for inclusion in the Board’s
Slate and the applicable Director Election Proxy Statement with respect to the election for which such failure occurred and such
Sponsor shall be deemed to have waived its rights hereunder with respect to such election; provided, further, however,
that any such waiver shall only be effective if the Company has provided written notice to such Sponsor of such Director Election
Proxy Statement no less than 20 business days, and no more than 40 business days, prior to the earlier of the mailing or filing
date of such Director Election Proxy Statement. The rights and remedies herein provided shall be cumulative and not exclusive of
any rights or remedies provided by law.


 


6.     Benefit
of Parties. This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective
permitted successors and assigns. Notwithstanding the foregoing, the Company may not assign any of its rights or obligations hereunder
without the prior written consent of each Sponsor that Beneficially Own shares of Common Stock representing at least 5% of the
Original Amount. Except as otherwise expressly provided in Section 7, nothing herein contained shall confer or is intended
to confer on any third party or entity that is not a party to this Agreement any rights under this Agreement.


 


7.     Assignment.
Upon written notice to the Company, each Sponsor may assign to any Affiliate (other than a portfolio company) all of its rights
hereunder and, following such assignment, such assignee shall be deemed to be a “Sponsor” for all purposes hereunder.


 






    8 


     


    

 



 


8.             Indemnification.


 


(a)            The
Company shall defend, indemnify and hold harmless the Sponsors, their respective Affiliates, partners, employees, agents, directors,
managers, officers and controlling Persons (collectively, the “Indemnified Parties”) from and against any and
all actions, causes of action, suits, claims, liabilities, losses, damages, costs, expenses, or obligations of any kind or nature
(whether accrued or fixed, absolute or contingent) in connection therewith (including reasonable attorneys’ fees and expenses)
incurred by the Indemnified Parties before or after the date of this Agreement (each, an “Action”) arising directly
or indirectly out of, or in any way relating to, (i) any Sponsor’s or its respective Affiliates’ Beneficial Ownership
of Common Stock or other equity securities of the Company or control or ability to influence the Company or any of its subsidiaries
(other than any such Actions (x) to the extent such Actions arise out of any breach of this Agreement by an Indemnified Party
or its Affiliates or the breach of any fiduciary or other duty or obligation of such Indemnified Party to its direct or indirect
equity holders, creditors or Affiliates or (y) to the extent such Actions are directly caused by such Person’s willful
misconduct), (ii) the business, operations, properties, assets or other rights or liabilities of the Company or any of its
subsidiaries or (iii) any services provided prior, on or after the date of this Agreement by any Sponsor or its respective
Affiliates to the Company or any of its subsidiaries. The Company shall defend at its own cost and expense in respect of any Action
which may be brought against the Company and/or its Affiliates and the Indemnified Parties. The Company shall defend at its own
cost and expense any and all Actions which may be brought in which the Indemnified Parties may be impleaded with others upon any
Action by the Indemnified Parties, except that if such damage shall be proven to be the direct result of gross negligence, bad
faith or willful misconduct by any of the Indemnified Parties, then such Indemnified Party shall reimburse the Company for the
costs of defense and other costs incurred by the Company in proportion to such Indemnified Party’s culpability as proven.
In the event of the assertion against any Indemnified Party of any Action or the commencement of any Action, the Company shall
be entitled to participate in such Action and in the investigation of such Action and, after written notice from the Company to
such Indemnified Party, to assume the investigation or defense of such Action with counsel of the Company’s choice at the
Company’s expense; provided, however, that such counsel shall be reasonably satisfactory to the Indemnified
Party. Notwithstanding anything to the contrary contained herein, the Company may retain one firm of counsel to represent all Indemnified
Parties in such Action; provided, however, that the Indemnified Party shall have the right to employ a single firm
of separate counsel (and any necessary local counsel) and to participate in the defense or investigation of such Action and the
Company shall bear the expense of such separate counsel (and local counsel, if applicable), if (x) in the opinion of counsel
to the Indemnified Party use of counsel of the Company’s choice could reasonably be expected to give rise to a conflict of
interest, (y) the Company shall not have employed counsel satisfactory to the Indemnified Party to represent the Indemnified
Party within a reasonable time after notice of the assertion of any such Action or (z) the Company shall authorize the Indemnified
Party to employ separate counsel at the Company’s expense. The Company further agrees that with respect to any Indemnified
Party who is employed, retained or otherwise associated with, or appointed or nominated by, the Sponsors or any of their respective
Affiliates and who acts or serves as a director, officer, manager, fiduciary, employee, consultant, advisor or agent of, for or
to the Company or any of its subsidiaries, that the Company or such subsidiaries, as applicable, shall be primarily liable for
all indemnification, reimbursements, advancements or similar payments (the “Indemnity Obligations”) afforded
to such Indemnified Party acting in such capacity or capacities on behalf or at the request of the Company, whether the Indemnity
Obligations are created by law, organizational or constituent documents, contract (including this Agreement) or otherwise. The
Company hereby agrees that in no event shall the Company or any of its subsidiaries have any right or claim against any Sponsor
for contribution or have rights of subrogation against any Sponsor through an Indemnified Party for any payment made by the Company
or any of its subsidiaries with respect to any Indemnity Obligation. In addition, the Company hereby agrees that in the event that
any Sponsor pay or advance an Indemnified Party any expenses with respect to an Indemnity Obligation, the Company will, or will
cause its subsidiaries to, as applicable, promptly reimburse any such Sponsor, respectively, for such payment or advance upon request;
subject to the receipt by the Company of a written undertaking executed by the Indemnified Party and the Sponsors, as applicable,
that makes such payment or advance to repay any such amounts if it shall ultimately be determined by a court of competent jurisdiction
that such Indemnified Party was not entitled to be indemnified by the Company. The foregoing right to indemnity shall be in addition
to any rights that any Indemnified Party may have at common law or otherwise and shall remain in full force and effect following
the completion or any termination of the engagement. If for any reason the foregoing indemnification is unavailable to any Indemnified
Party or insufficient to hold it harmless as and to the extent contemplated by this Section 8, then the Company shall
contribute to the amount paid or payable by the Indemnified Party as a result of such Action in such proportion as is appropriate
to reflect the relative benefits received by the Company, on the one hand, and the Indemnified Party, as the case may be, on the
other hand, as well as any other relevant equitable considerations.


 






    9


     


    

 


(b)            The
Company hereby acknowledges that the certain of the Indemnified Parties have certain rights to indemnification, advancement of
expenses and/or insurance provided by investment funds managed by Apax Partners and WCAS and certain of their Affiliates (collectively,
the “Fund Indemnitors”). The Company hereby agrees with respect to any indemnification, hold harmless obligation,
expense advancement or reimbursement provision or any other similar obligation whether pursuant to or with respect to this Agreement,
the organizational documents of the Company or any of its subsidiaries or any other agreement, as applicable, (i) that the
Company and its subsidiaries are the indemnitor of first resort (i.e., their obligations to the Indemnified Parties are primary
and any obligation of the Fund Indemnitors to advance expenses or to provide indemnification for claims, expenses or obligations
arising out of the same or similar facts and circumstances suffered by any Indemnified Party are secondary), (ii) that the
Company shall be required to advance the full amount of expenses incurred by any Indemnified Party and shall be liable for the
full amount of all expenses, liabilities, obligations, judgments, penalties, fines, and amounts paid in settlement to the extent
legally permitted and as required by the terms of this Agreement, the organizational documents of the Company or any of its subsidiaries
or any other agreement, as applicable, without regard to any rights any Indemnified Party may have against the Fund Indemnitors,
and (iii) that the Company, on behalf of itself and each of its subsidiaries, irrevocably waives, relinquishes and releases
the Fund Indemnitors from any and all Actions against the Fund Indemnitors for contribution, subrogation or any other recovery
of any kind in respect thereof. The Company further agrees that no advancement or payment by the Fund Indemnitors on behalf of
any Indemnified Party with respect to any Action for which any Indemnified Party has sought indemnification from the Company shall
affect the foregoing and the Fund Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement
or payment to all of the rights of recovery of any Indemnified Party against the Company. The Company agrees that the Fund Indemnitors
are express third-party beneficiaries of the terms of this Section 8(b).


 


9.             Headings.
Headings are for ease of reference only and shall not form a part of this Agreement.


 


10.           Governing
Law. This Agreement shall be construed in accordance with and governed by the law of the State of Delaware without giving effect
to the principles of conflicts of laws thereof.


 


11.           Jurisdiction.
Any suit, action or proceeding seeking to enforce any provision of, or based on any matter arising out of or in connection with,
this Agreement may be brought against any of the parties in any federal court located in the State of Delaware or any Delaware
state court, and each of the parties hereby consents to the exclusive jurisdiction of such court (and of the appropriate appellate
courts) in any such suit, action or proceeding and waives any objection to venue laid therein. Process in any such suit, action
or proceeding may be served on any party anywhere in the world, whether within or without the jurisdiction of any such court. Without
limiting the foregoing, each of the parties agrees that service of process upon such party at the address referred to in Section 18,
together with written notice of such service to such party, shall be deemed effective service of process upon such party.


 






    10


     


    

 


12.           WAIVER
OF JURY TRIAL. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING
ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT.


 


13.           Entire
Agreement. This Agreement constitutes the entire agreement among the parties with respect to the subject matter hereof and
supersedes all prior agreements, understandings and negotiations, both written and oral among the parties with respect to the subject
matter hereof.


 


14.           Counterparts;
Effectiveness. This Agreement may be signed in any number of counterparts, each of which shall be deemed an original. This
Agreement shall become effective when each party shall have received a counterpart hereof signed by each of the other parties.
An executed copy or counterpart hereof delivered by facsimile shall be deemed an original instrument.


 


15.           Severability.
If any provision of this Agreement or the application thereof to any person or circumstance shall be invalid or unenforceable to
any extent, the remainder of this Agreement and the application of such provisions to other persons or circumstances shall not
be affected thereby and shall be enforced to the greatest extent permitted by law.


 


16.           Further
Assurances. Each of the parties hereto shall execute and deliver such further instruments and do such further acts and things
as may be required to carry out the intent and purpose of this Agreement.


 


17.           Specific
Performance. Each of the parties hereto agree that irreparable damage would occur if any provision of this Agreement were not
performed in accordance with the terms hereof and that the parties shall be entitled to an injunction or injunctions to prevent
breaches of this Agreement or to enforce specifically the performance of the terms and provisions hereof in any federal or state
court located in the State of Delaware, in addition to any other remedy to which they are entitled at law or in equity.


 


18.           Notices.
All notices, requests and other communications to any party or to the Company shall be in writing (including telecopy or similar
writing) and shall be given,


 


If
to the Company:


 


InnovAge Holding Corp.


8950 E. Lowry Boulevard


Denver, Colorado 80230


Attention: Chief Legal
Officer


 






    11


     


    

 


With
a copy to (which shall not constitute notice):


 


Kirkland &
Ellis LLP


300 N. LaSalle


Chicago, IL 60654


Attention: Robert
M. Hayward, P.C.


   Robert E. Goedert,
P.C.


Facsimile: (312) 862-2200


 


If
to any member of Apax Partners or any of its Nominees:


 


c/o Apax Partners, L.P.


601 Lexington Avenue


53rd Floor


New York, New York 10022


Attention: [***]


Email:
[***]@apax.com


 


If
to any member of WCAS or any of its Nominees:


 


c/o Welsh, Carson,
Anderson & Stowe, L.P.


599 Lexington Avenue


Suite 1800


New York, New York
10022


Attention: [***]


Email:
[***]@wcas.com


 


With
a copy to (which shall not constitute notice):


 


Kirkland &
Ellis LLP


300 N. LaSalle


Chicago, IL 60654


Attention: Robert
M. Hayward, P.C.


   Robert E. Goedert,
P.C.


Facsimile: (312) 862-2200


 


or to such other address or telecopier
number as such party or the Company may hereafter specify for the purpose by notice to the other parties and the Company. Each
such notice, request or other communication shall be effective when delivered at the address specified in this Section 18
during regular business hours.


 


19.           Enforcement.
Each of the parties hereto covenants and agrees that the disinterested members of the Board have the right to enforce, waive or
take any other action with respect to this Agreement on behalf of the Company.


 


* * * * *


 






    12


     


    

 


IN WITNESS WHEREOF, the parties hereto have
executed this Agreement on the date first above written.


 


	 	INNOVAGE HOLDING CORP.




 


	 	By:	/s/ Vanessa D. Walton







	 	Name: Vanessa D. Walton
	 	Title:    Secretary




 


 


[Signature Page to Director Nomination Agreement]


 






    


     


    

 


	 	ignite aggregator lp




 


	 	By:  Ignite GP Inc., its general partner




 


	 	By:	/s/ Andrew Cavanna







	 	Name:    Andrew Cavanna
	 	Title:      President




 


[Signature Page to Director Nomination Agreement]


 






    


     


    

 


	 	Welsh, Carson, Anderson & Stowe XII, L.P.




 


	 	By: WCAS XII Associates LLC, its general partner




 


	 	By:	/s/ Thomas Scully







	 	Name:    Thomas Scully
	 	Title:      Managing Member




 


	 	Welsh, Carson, Anderson & Stowe XII Delaware, L.P.




 


	 	By: WCAS XII Associates Cayman, L.P., its general partner




 


	 	By: WCAS XII Associates LLC, its general partner




 


	 	By:	/s/ Thomas Scully







	 	Name:   Thomas Scully
	 	Title:      Managing Member




 


	 	Welsh, Carson, Anderson & Stowe XII Delaware II, L.P.




 


	 	By: WCAS XII Associates LLC, its general partner




 





	 	By:	/s/ Thomas Scully





	 	Name:   Thomas Scully
	 	Title:      Managing Member





 


[Signature Page to Director Nomination Agreement]


 






    


     


    

 


	 	Welsh, Carson, Anderson & Stowe XII Cayman, L.P.




 


	 	By: WCAS XII Associates Cayman, L.P., its general partner




 


	 	By: WCAS XII Associates LLC, its general partner




 


	 	By:	/s/ Thomas Scully








	 	Name:   Thomas Scully
	 	Title:      Managing Member








 


	 	WCAS XII Co-Investors LLC




 


	 	By:	/s/ Jonathan Rather





	 	Name:    Jonathan Rather
	 	Title:      Managing Member




 


	 	WCAS Management Corporation




 


	 	By:	/s/ Jonathan Rather





	 	Name:    Jonathan Rather
	 	Title:     Treasurer







 


	 	WCAS Co-Invest Holdco, L.P.




 


	 	By: WCAS Co-Invest Associates LLC, its general partner




 


	 	By:	/s/ Jonathan Rather





 


	 	Name:    Jonathan Rather
	 	Title:      Managing Member








 


[Signature Page to Director
Nomination Agreement]